Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

This bill requires health insurers in New Jersey to cover insulin without deductibles and limits patient copayments or coinsurance for insulin to $50 per 30-day supply. It applies to all health insurance plans covering diabetes treatment, including individual, group, and employer-sponsored plans. The bill also mandates insulin manufacturers to submit annual reports to the Commissioner of Banking and Insurance detailing pricing, sales, and research costs. These provisions aim to reduce financial barriers to insulin access for New Jersey residents with diabetes.